Diseases /
Prostate Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: One of the most common malignant tumors afflicting men. The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland. Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes. Adenocarcinomas represent the overwhelming majority of prostatic carcinomas. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease. [1]
Biomarker-Directed Therapies
Of the biomarker-directed therapies for prostate carcinoma, 2 are FDA-approved in at least one setting and 2 have NCCN guidelines in at least one setting [3].
Olaparib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
ATM Mutation, BRCA1 Mutation, BRCA2 Mutation, FANCL Mutation, PALB2 Mutation, ATM Loss, BARD1 Loss, BARD1 Mutation, BRCA1 Loss, BRCA2 Loss, BRIP1 Loss, BRIP1 Mutation, CDK12 Loss, CDK12 Mutation, CHEK1 Loss, CHEK1 Mutation, CHEK2 Loss, CHEK2 Mutation, FANCL Loss, PALB2 Loss, RAD51B Loss, RAD51B Mutation, RAD51C Loss, RAD51C Mutation, RAD51D Loss, RAD51D Mutation, RAD54L Loss, RAD54L Mutation |
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Approved for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. |
Rucaparib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Indicated for deleterious BRCA mutations (germline and/or somatic) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. |
Clinical Trials
There are 241 clinical trials for prostate carcinoma, of which 193 are open and 48 are completed or closed. Of the trials that contain prostate carcinoma as an inclusion criterion, 5 are early phase 1 (5 open), 76 are phase 1 (51 open), 48 are phase 1/phase 2 (41 open), 71 are phase 2 (62 open), 20 are phase 3 (18 open), 2 are phase 4 (2 open), and 19 are no phase specified (14 open).
BRCA1, BRCA2, and ATM are the most frequent gene inclusion criteria for prostate carcinoma clinical trials [3].
Enzalutamide, docetaxel, and prednisone are the most common interventions in prostate carcinoma clinical trials.
Significant Genes in Prostate Carcinoma
AKT1 +
AKT1 is an inclusion eligibility criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [3].
AKT2 +
AKT2 is an inclusion eligibility criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT2 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [3].
AKT3 +
AKT3 is an inclusion eligibility criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [3].
ALK +
ALK is an inclusion eligibility criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
ARID1A +
ARID1A is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ARID1A status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
ATM +
ATM is an inclusion eligibility criterion in 23 clinical trials for prostate carcinoma, of which 18 are open and 5 are closed. Of the trials that contain ATM status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 14 are phase 2 (11 open), and 2 are phase 3 (2 open) [3].
Olaparib has evidence of efficacy in patients with ATM mutation in prostate carcinoma [3].
ATR +
ATR is an inclusion eligibility criterion in 12 clinical trials for prostate carcinoma, of which 8 are open and 4 are closed. Of the trials that contain ATR status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].
ATRX +
ATRX is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ATRX status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
AXL +
AXL is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
BACH1 +
BACH1 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BACH1 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
BARD1 +
BARD1 is an inclusion eligibility criterion in 17 clinical trials for prostate carcinoma, of which 13 are open and 4 are closed. Of the trials that contain BARD1 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with BARD1 mutation in prostate carcinoma [3].
BRAF +
BRAF is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
BRCA1 +
BRCA1 is an inclusion eligibility criterion in 25 clinical trials for prostate carcinoma, of which 19 are open and 6 are closed. Of the trials that contain BRCA1 status and prostate carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 15 are phase 2 (11 open), and 2 are phase 3 (2 open) [3].
Olaparib and rucaparib have evidence of efficacy in patients with BRCA1 mutation in prostate carcinoma [3].
BRCA2 +
BRCA2 is an inclusion eligibility criterion in 25 clinical trials for prostate carcinoma, of which 19 are open and 6 are closed. Of the trials that contain BRCA2 status and prostate carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 15 are phase 2 (11 open), and 2 are phase 3 (2 open) [3].
Olaparib and rucaparib have evidence of efficacy in patients with BRCA2 mutation in prostate carcinoma [3].
BRIP1 +
BRIP1 is an inclusion eligibility criterion in 19 clinical trials for prostate carcinoma, of which 15 are open and 4 are closed. Of the trials that contain BRIP1 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 11 are phase 2 (9 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with BRIP1 mutation in prostate carcinoma [3].
C11ORF30 +
C11orf30 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain C11orf30 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
CCND1 +
CCND1 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
CDK12 +
CDK12 is an inclusion eligibility criterion in 18 clinical trials for prostate carcinoma, of which 14 are open and 4 are closed. Of the trials that contain CDK12 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with CDK12 mutation in prostate carcinoma [3].
CDK4 +
CDK4 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
CDKN2A +
CDKN2A is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
CHEK1 +
CHEK1 is an inclusion eligibility criterion in 15 clinical trials for prostate carcinoma, of which 11 are open and 4 are closed. Of the trials that contain CHEK1 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with CHEK1 mutation in prostate carcinoma [3].
CHEK2 +
CHEK2 is an inclusion eligibility criterion in 16 clinical trials for prostate carcinoma, of which 12 are open and 4 are closed. Of the trials that contain CHEK2 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with CHEK2 mutation in prostate carcinoma [3].
CRKL +
CRKL is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
EGFR +
EGFR is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
ERBB2 +
ERBB2 is an inclusion eligibility criterion in 4 clinical trials for prostate carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and prostate carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [3].
ERCC2 +
ERCC2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERCC2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
ERCC3 +
ERCC3 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERCC3 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
ERCC4 +
ERCC4 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERCC4 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
ERCC5 +
ERCC5 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERCC5 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
ERCC6 +
ERCC6 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERCC6 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
FANCA +
FANCA is an inclusion eligibility criterion in 18 clinical trials for prostate carcinoma, of which 14 are open and 4 are closed. Of the trials that contain FANCA status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
FANCB +
FANCB is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 9 are open and 4 are closed. Of the trials that contain FANCB status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
FANCC +
FANCC is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 9 are open and 4 are closed. Of the trials that contain FANCC status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
FANCD2 +
FANCD2 is an inclusion eligibility criterion in 14 clinical trials for prostate carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCD2 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
FANCE +
FANCE is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 9 are open and 4 are closed. Of the trials that contain FANCE status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
FANCF +
FANCF is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 9 are open and 4 are closed. Of the trials that contain FANCF status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
FANCG +
FANCG is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 9 are open and 4 are closed. Of the trials that contain FANCG status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
FANCI +
FANCI is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 9 are open and 4 are closed. Of the trials that contain FANCI status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
FANCL +
FANCL is an inclusion eligibility criterion in 15 clinical trials for prostate carcinoma, of which 11 are open and 4 are closed. Of the trials that contain FANCL status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with FANCL mutation in prostate carcinoma [3].
FANCM +
FANCM is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 9 are open and 4 are closed. Of the trials that contain FANCM status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
FLT1 +
FLT1 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT3 +
FLT3 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT4 +
FLT4 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
GEN1 +
GEN1 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains GEN1 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain HDAC1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain HDAC2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
HRAS +
HRAS is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
IDH1 +
IDH1 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
IDH2 +
IDH2 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
KDR +
KDR is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
KIT +
KIT is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
KRAS +
KRAS is an inclusion eligibility criterion in 3 clinical trials for prostate carcinoma, of which 1 is open and 2 are closed. Of the trials that contain KRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 7 clinical trials for prostate carcinoma, of which 3 are open and 4 are closed. Of the trials that contain MCPH1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].
MDM2 +
MDM2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MDM2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MDM4 +
MDM4 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MDM4 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MET +
MET is an inclusion eligibility criterion in 3 clinical trials for prostate carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MET status and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MLF1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MLH1 +
MLH1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MLH1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MLH3 +
MLH3 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MLH3 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MRE11A +
MRE11A is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 9 are open and 4 are closed. Of the trials that contain MRE11A status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
MSH2 +
MSH2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MSH2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MSH3 +
MSH3 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MSH3 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MSH6 +
MSH6 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MSH6 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MTAP +
MTAP is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MTOR +
MTOR is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
MUTYH +
MUTYH is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MUTYH status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MYC +
MYC is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
NBN +
NBN is an inclusion eligibility criterion in 16 clinical trials for prostate carcinoma, of which 12 are open and 4 are closed. Of the trials that contain NBN status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].
NPM1 +
NPM1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain NPM1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
NRAS +
NRAS is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
NTRK1 +
NTRK1 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
NTRK2 +
NTRK2 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
NUTM1 +
NUTM1 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NUTM1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
PALB2 +
PALB2 is an inclusion eligibility criterion in 20 clinical trials for prostate carcinoma, of which 16 are open and 4 are closed. Of the trials that contain PALB2 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 12 are phase 2 (10 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with PALB2 mutation in prostate carcinoma [3].
PARP1 +
PARP1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PARP1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PARP2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
PDGFRA +
PDGFRA is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
PIK3CA +
PIK3CA is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
PIK3CB +
PIK3CB is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and prostate carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
PIK3CG +
PIK3CG is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
PIK3R1 +
PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
PIK3R2 +
PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
PMS1 +
PMS1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PMS1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
PMS2 +
PMS2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PMS2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
POLE +
POLE is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain POLE status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
PPP2R1A +
PPP2R1A is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PPP2R1A status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 7 clinical trials for prostate carcinoma, of which 6 are open and 1 is closed. Of the trials that contain PPP2R2A status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
PTEN +
PTEN is an inclusion eligibility criterion in 15 clinical trials for prostate carcinoma, of which 8 are open and 7 are closed. Of the trials that contain PTEN status and prostate carcinoma as inclusion criteria, 5 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), 5 are phase 2 (3 open), and 2 are phase 3 (2 open) [3].
RAD50 +
RAD50 is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 9 are open and 4 are closed. Of the trials that contain RAD50 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
RAD51 +
RAD51 is an inclusion eligibility criterion in 16 clinical trials for prostate carcinoma, of which 12 are open and 4 are closed. Of the trials that contain RAD51 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].
RAD51B +
RAD51B is an inclusion eligibility criterion in 15 clinical trials for prostate carcinoma, of which 11 are open and 4 are closed. Of the trials that contain RAD51B status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with RAD51B mutation in prostate carcinoma [3].
RAD51C +
RAD51C is an inclusion eligibility criterion in 18 clinical trials for prostate carcinoma, of which 14 are open and 4 are closed. Of the trials that contain RAD51C status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with RAD51C mutation in prostate carcinoma [3].
RAD51D +
RAD51D is an inclusion eligibility criterion in 17 clinical trials for prostate carcinoma, of which 13 are open and 4 are closed. Of the trials that contain RAD51D status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with RAD51D mutation in prostate carcinoma [3].
RAD54L +
RAD54L is an inclusion eligibility criterion in 15 clinical trials for prostate carcinoma, of which 11 are open and 4 are closed. Of the trials that contain RAD54L status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with RAD54L mutation in prostate carcinoma [3].
RB1 +
RB1 is an inclusion eligibility criterion in 3 clinical trials for prostate carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RB1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].
RET +
RET is an inclusion eligibility criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
RICTOR +
RICTOR is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
ROS1 +
ROS1 is an inclusion eligibility criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
RPTOR +
RPTOR is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
SLX4 +
SLX4 is an inclusion eligibility criterion in 12 clinical trials for prostate carcinoma, of which 8 are open and 4 are closed. Of the trials that contain SLX4 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].
SMARCB1 +
SMARCB1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain SMARCB1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
STAG2 +
STAG2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain STAG2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
STK11 +
STK11 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain STK11 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
TEK +
TEK is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
TP53 +
TP53 is an inclusion eligibility criterion in 5 clinical trials for prostate carcinoma, of which 3 are open and 2 are closed. Of the trials that contain TP53 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [3].
TSC1 +
TSC1 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
TSC2 +
TSC2 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
WNT5A +
WNT5A is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains WNT5A status and prostate carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
XRCC1 +
XRCC1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain XRCC1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
